Cancer Focus Fund, a venture capital arm of Houston-based University of Texas MD Anderson Cancer Center, has joined a $25 million series A funding round for Nectin Therapeutics, which develops novel immunotherapies.
Read the full post on Becker's Hospital Review - Healthcare News
